Genomic Visions: Cempra – Oral and Intravenous Fluoroketolid to Improve Community Health

Cempra (CEMP) is a biotechnology company focused on creating a new antibiotic, which may be “the next generation oral and intravenous fluoroketolid.” The company’s main antibiotic, Solithromycin, is currently in a Phase III study for community acquired bacterial pneumonia, as well as a mid-stage trial for gonorrhea.

Read more »